Dr Shom Goel has received a USD $243,000 (Approximately AUD $342,000) ASPIRE grant from US-based philanthropic organisation The Mark Foundation for Cancer Research.

Since 2017, The Mark Foundation has awarded more than USD $125 million in grants to enable innovative basic, translational, and clinical cancer research including drug discovery, primarily to researchers in the US and Europe.

This is the first time Australian projects have attracted Mark Foundation funding.

“I am delighted to receive this grant, and not only because it will further my work to understand cellular senescence and how this could support a new class of cancer therapeutics,” says Dr Goel, who is a Consultant Oncologist at Peter Mac and group Leader in the Cancer Research Division.

“It is fantastic to see The Mark Foundation, which ranks among the world’s major philanthropic supporters of cancer research, extend its reach to Australia.”

Also in this ASPIRE funding round, Monash University’s Associate Professor Ross Dickins receives USD $232,000 (AUD $325,000) to support his research into preventing relapse following acute myeloid leukemia differentiation therapy.

The ASPIRE (Accelerating Scientific Platforms and Innovative Research) program supports high-risk, high-reward projects that answer key feasibility and proof-of-concept questions in a short timeframe, typically one year, and success can lead to more Mark Foundation funding.

Ryan Schoenfeld, PhD, Mark Foundation Chief Scientific Officer and interim CEO, says: “as The Mark Foundation increases our financial commitment to tackling the greatest challenges in cancer, we are excited to expand our global outreach in pursuing outstanding scientific research projects”.

“We welcome these distinguished Australian researchers and institutions into our growing global family of funded investigators.”

For more information contact the Peter Mac Communications team on 0417 123 048.

About Peter Mac

Peter MacCallum Cancer Centre is a world-leading cancer research, education and treatment centre and Australia’s only public health service solely dedicated to caring for people affected by cancer.

About The Mark Foundation for Cancer Research

The Mark Foundation for Cancer Research actively partners with scientists to accelerate research that will transform the prevention, diagnosis, and treatment of cancer. The Mark Foundation fulfills its mission by supporting groundbreaking science carried out by individual investigators, multi-disciplinary teams, and inter-institutional collaborations in the United States, Europe, and across the globe. Recognizing the obstacles that prevent scientific advances from improving patient outcomes, The Mark Foundation maintains a nimble, high-impact approach to funding cancer research that bridges the gap between bench and bedside through grants and early-stage venture investments. Since 2017, The Mark Foundation has awarded more than $125 million in grants to enable innovative basic, translational, and clinical cancer research, including drug discovery. The Mark Foundation also has a robust and growing portfolio of investments in oncology companies developing novel therapeutics and diagnostics. Through its research and venture arms, The Mark Foundation supports projects throughout their life cycle to ensure their highest chance of success in impacting the lives of patients with breakthroughs in cancer care.

To learn more please visit www.TheMarkFoundation.org.